Compare TRX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | IMMX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.5M | 306.2M |
| IPO Year | N/A | 2021 |
| Metric | TRX | IMMX |
|---|---|---|
| Price | $0.93 | $4.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.30 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.1M | 923.4K |
| Earning Date | 01-14-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,202,000.00 | N/A |
| Revenue This Year | $93.43 | N/A |
| Revenue Next Year | $44.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 58.53 | N/A |
| 52 Week Low | $0.27 | $1.34 |
| 52 Week High | $1.04 | $7.73 |
| Indicator | TRX | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 47.37 |
| Support Level | $0.90 | $4.54 |
| Resistance Level | $1.04 | $5.09 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 43.65 | 48.93 |
TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.